Thrombin receptor expression is upregulated in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Aberrant protease-activated receptor (PAR) expression is linked to cancer angiogenesis, growth, and metastasis.
• Protease-activated receptor 1 (PAR1) is implicated in various cancer pathologies.
• The role of PAR1 in prostate cancer progression requires further investigation.

Purpose of the Study:

• To assess the expression status of PAR1 in prostate cancer tissues.
• To investigate the correlation between PAR1 expression and prostate cancer stage.
• To explore PAR1's potential role in prostate cancer angiogenesis and progression.

Main Methods:

• Compared PAR1 RNA and protein levels in early vs. advanced prostate cancer using RT-PCR and immunoblotting.
• Utilized immunohistochemical staining to evaluate PAR1 expression and localization in benign and malignant prostate tissues.
• Analyzed associations between PAR1 expression and VEGF family factors, receptors, and clinicopathological features.

Main Results:

• PAR1 RNA and protein expression were significantly higher in advanced-stage prostate cancer compared to early-stage.
• PAR1 was predominantly localized to endothelial cells within the prostate tumor vascular network.
• PAR1 expression correlated significantly with advanced disease stage and elevated pre-operative PSA levels.

Conclusions:

• PAR1 expression is upregulated in prostate cancer, particularly in the tumor vasculature.
• PAR1's localization suggests a crucial role in tumor angiogenesis.
• PAR1 represents a potential therapeutic target for managing prostate cancer progression.